Eli Lilly’s Ebglyss (lebrikizumab) will require strategic market positioning to differentiate it against more established ...

Eli Lilly and Company has announced FDA approval of EBGLYSS (lebrikizumab-lbkz) to treat moderate-to-severe atopic dermatitis ...

The launch of Almirall’s eczema treatment, Ebglyss (lebrikizumab), generated $22 million in sales across initial European markets, while Ilumetri (tildrakizumab) for psoriasis saw sales rise 24.8% ...

David Risinger’s rating is based on the promising topline data from Eli Lilly’s Phase 3b ADapt trial, which showcased the effectiveness of Ebglyss (lebrikizumab) for patients with moderate-to ...

Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.

Patients in this study saw improvements in difficult-to-treat areas when treated with Ebglyss. With Ebglyss, 57% of patients in Week 16 and 60% in Week 24 who had previously been treated with ...

The US approval of Eli Lilly’s Ebglyss (lebrikizumab) in September 2024 places the company in a competitive position in the atopic dermatitis (AD) market. AD, also known as eczema, is a chronic ...

Eli Lilly (NYSE:LLY) said a Phase 3b study of its drug Ebglyss showed it was able to improve skin and itch in patients with moderate-to-severe atopic dermatitis who had previously been treated ...

The new product approvals for Ebglyss and Kisunla, exciting new pipeline data for tirzepatide, donanemab, imlunestrant and lebrikizumab, as well as key milestone achievements in our supply network ...

On Friday, Eli Lilly and Company (NYSE:LLY) revealed new results from the Phase 3b ADapt study of Ebglyss (lebrikizumab), ...